ENHANCEMENT OF PROGNOSTIC VALUE OF GENE IL28B POLYMORPHISM IN COMBINATION WITH QUANTITATIVE ASSESSMENT OF IP-10 IN SERUM IN RESPONSE TO PEGINTERFERON AND RIBAVIRIN IN COMPARISON WITH EACH OF THEM SEPARATELY Russian patent published in 2015 - IPC C12Q1/68 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to biotechnology, namely to a method of combining determination of the IL28B genotype with the measurement of the serum level of the IFN-γ-induced protein 10 (IP-10) for the prediction of obtaining a stable virologic response (SVR) or the absence of response to peginterferon and ribavirin for individual HCV-infected patients, as well as to a diagnostic set for the application in the claimed method. The method includes the determination of the IL28B genotype by means of the polymorphic marker rs12979860 and serum level of IP-10 in groups with the IL28B genotype, which provides additional and independent information with respect to SVR probability. Carriers of CC with IP-10<600 pg/ml have 100% SVR probability and 75% probability, when IP-10>600 pg/ml. The carrier of CT with IP-10<600 pg/ml have 79% SVR probability and 34% probability, when IP-10>600 pg/ml. The carrier of TT with IP-10<600 pg/ml have 50% SVR probability and 10% probability, when IP-10>600 pg/ml.

EFFECT: invention makes it possible to obtain information about a stable virologic response to peginterferon and ribavirin in individual HCV-infected patients.

7 cl, 15 dwg, 4 tbl